Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert/RPR sparfloxacin agreement

Executive Summary

Warner-Lambert and Rhone-Poulenc Rorer will co-promote the oral quinolone antibiotic in the U.S. and Canada under a development agreement announced April 1. Warner-Lambert licensed sparfloxacin from Japan's Dainippon in 1989. Rhone-Poulenc Rorer will conduct clinical studies of the product, which is expected soon to enter Phase III for community acquired infections and is already in Phase III for skin infections, pneumonia, bronchitis and complicated urinary tract infections. RPR already has an agreement with Dainippon to develop and market sparfloxacin in Europe. Warner-Lambert will continue its Phase I studies of sparfloxacin for Mycobacterium avium complex in AIDS patients, an indication not included in the co-development deal ("The Pink Sheet" March 23, T&G-5).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel